LEXX Message Board Post 10865142 | Lexaria Bioscience Corp.
home / stock / lexx / lexx message board
Ceese
(investorshangout)
Posted on: Apr/05/2023 21:33:29
Source: investorshangout
https://investorshangout.com/post/view?id=6557325
NetworkNewsWire: Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Multiple Commercial Applications for Its Patent
News, Short Squeeze, Breakout and More Instantly...
-
Lexaria, a global innovator in drug delivery platforms, recently completed dosing of its human pilot study #2, GLP-1-H24-2 The study is to explore the tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug For Lexaria, the results f...
-
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1. The company noted that the results have already produced several notewort...
-
(TheNewswire) DehydraTECH appears to work with a second GLP-1 drug – liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 D...